Episode Details

#Ozempic #GLP1 #Semaglutide #WeightLossJourney #ObesityMedicine

Most Ozempic and Mounjaro side effects are just uncomfortable — but a few can land you in the ER. In this video, Dr. Mohammed Paika (board-certified internal medicine + obesity medicine physician, 15+ years as a hospitalist) breaks down which GLP-1 side effects are genuinely dangerous, who's at higher risk, and the exact red-flag symptoms you should never wait out.

What's covered:

Why GLP-1 side effects happen (the mechanism in plain terms)
Nausea/vomiting: normal vs. red flag
Dehydration and acute kidney injury
DKA risk for diabetics on GLP-1s
Gallbladder disease and pancreatitis
Gastroparesis, explained without the internet hype
The thyroid cancer warning — what the label actually means
Muscle loss: the side effect no one talks about (and how to prevent it)
Mood changes and when to get help
A full red-flag quick-reference recap

This video is for education, not medical advice — always talk to your own prescriber about your specific situation.

Want the full system for nutrition, protein targets, training, and side-effect management on GLP-1 medications? Join the GLP-1 Masterclass at https://drmohammedpaika.com

If this helped, subscribe for the next video on structuring protein and training week-by-week on these medications.

If you or someone you know is struggling with thoughts of self-harm, call or text 988 (Suicide & Crisis Lifeline).

GLP-1 Weight Loss Masterclass - https://www.drmohammedpaika.com
Dr. Paika Podcast - https://drmohammedpaika.transistor.fm/ 
Amazon Kindle - https://www.amazon.it/GLP-1-Masterclass-Physicians-Preservation-Metabolic-ebook/dp/B0GZBR8MC4

Timestamps
0:00 Intro
0:49 Who I Am
2:58 Why GLP-1 Side Effects Happen
3:57 Nausea & Vomiting: Where It Usually Starts
5:05 Dehydration & Acute Kidney Injury
7:41 Starvation Ketosis & DKA Risk
9:37 Quick Note: GLP-1 Masterclass
10:17 Gallbladder Disease & Pancreatitis
12:35 Gastroparesis: The Internet-Famous One
14:01 The Thyroid Cancer Myth
15:55 Muscle Wasting: The One I See Most Often
19:13 Mood Changes & Depression
21:01 Who Is At Higher Risk: The Summary
21:59 The Red Flags: Quick Recap
22:43 Close & Next Steps

References:
FDA Prescribing Information — Ozempic (semaglutide): [accessdata.fda.gov label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf)

FDA Prescribing Information — Mounjaro (tirzepatide): [accessdata.fda.gov label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s039lbl.pdf)

FDA Prescribing Information — Zepbound (tirzepatide): [accessdata.fda.gov label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf)
(Wegovy shares the same active ingredient, semaglutide, and labeling basis as Ozempic.)

Wilding JPH, et al. STEP 1 body composition sub-study — DEXA data on fat vs. lean mass loss: [J Endocr Soc](https://academic.oup.com/jes/article/5/Supplement_1/A16/6240360)

Look M, et al. SURMOUNT-1 body composition sub-study — lean mass findings on tirzepatide: [Diabetes Obes Metab, 2025](https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.16275)

Bjerre Knudsen L, et al. Endocrinology 2010;151(4):1473-1486 — the rodent thyroid C-cell study behind the boxed warning: [Oxford Academic](https://academic.oup.com/endo/article/151/4/1473/2456651)

👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKA
Board-Certified in Internal Medicine and Obesity Medicine
Certified Personal Trainer & Nutrition Coach
Helping people understand metabolism, hormones, and sustainable health through evidence-based medicine.

👍 Like
💬 Comment
📌 Share
🔔 Subscribe for more honest conversations about obesity, metabolism, hormones, and real-world health solutions

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER
This channel and its content are provided by Dr. Mohamm